Clues to primary vismodegib resistance lie in histology and genetics.

Basal cell carcinoma (BCC) is the most common human malignant neoplasm. However, there are multiple BCC subtypes that share clinical features while demanding different management. We present a case of a woman with hundreds of BCCs throughout her body that were resistant to vismodegib and without other features of basal cell nevus syndrome. Histological results of biopsies taken from various sites revealed three lesions characteristic of infundibulocystic BCCs (IBCCs) and two BCCs. Paired whole-exome sequencing performed using DNA isolated from blood and one of her IBCCs uncovered a germline heterozygousSUFU(Suppressor of Fused) mutation. The downstream location ofSUFUin the hedgehog pathway explains why its mutation results in IBCCs that will not respond to any therapeutics that target upstream components ofSUFU. These results capture the significance of histological and genetic analysis in directing treatment.